# Singlomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/singlomics

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.singlomics.com
- Total disclosed funding: $62M
- Latest round: Series B (Feb 12, 2022)
- Investors on record: 12

## About

Established in 2020 and based in Beijing, China, the company has a team of 26 people, of which the core scientific team members have graduated from Harvard University, Peking University, Fudan University and other well-known institutions. The company has completed a series A round of nearly $100 million funding from top Chinese health care investors, and developed two products DXP593 and DXP604, for the treatment and prevention of COVID-19. The co-founder of the company professor Xiaoliang Xie is an internationally renowned biophysical chemist and a member of the US National Academy of Sciences, the CEO Dr. Qian Shi used to work in Apollomics and other companies in the field of oncology. 

The company owns a single cell sequencing platform, is a novel drug development strategy which can be used to develop antibody-based drugs. Based on the above platform, the company's drug development pipeline consists of three main directions: covid-19 neutralizing antibody, the main products are DXP-593 and DXP-604, which can be used to defend Delta and Omicron; antibodies to infectious diseases for resistance to chronic hepatitis B; and drugs applied in oncology treatment.

In 2022, Singlomics received a CNY 300 million series B funding, which will contribute to the company’s investment in further enhance the new pipeline while developing a new crown pneumonia neutralizing antibody.

## Funding rounds

- Series B, Feb 12, 2022, $47M — Legend Capital, MSA Capital, CASH Capital, Shanghai Jianyi Private Equity Fund Management, Huagai Capital, Founder H Fund, Everbright ReinFore, Witruth Capital, Bohe Angel Fund, GL Ventures
- Series A, Sep 4, 2020, $15M — Huagai Capital, Beijing Capital Science and Technology Development Group Investment Management, Changkejin  Investment, Bohe Angel Fund, GL Ventures

## Investors

- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A, Series B
- Beijing Capital Science and Technology Development Group Investment Management (https://capitalatlas.ai/funds/beijing-capital-science-and-technology-development-group-inv) — Series A
- Changkejin  Investment — Series A
- Bohe Angel Fund — Series A, Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A, Series B
- Legend Capital — Series B
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series B
- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series B
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- Founder H Fund (https://capitalatlas.ai/funds/founder-h-fund) — Series B
- Everbright ReinFore (https://capitalatlas.ai/funds/everbright-reinfore) — Series B
- Witruth Capital — Series B